Carboplatin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mg/5 mL , 150 mg/15 mL, 450 mg/45 mL
Reference Brands: Paraplatin® (EU & US)
Category:
Oncology Cancer Care
Carboplatin is an intravenous chemotherapy used for ovarian, lung, head and neck, and testicular cancer. Available in 50 mg/5 mL, 150 mg/15 mL, and 450 mg/45 mL injections in the US and EU.
Carboplatin is available in Injection
and strengths such as 50 mg/5 mL , 150 mg/15 mL, 450 mg/45 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Carboplatin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Carboplatin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Carboplatin, marketed as Paraplatin®, is a platinum-based chemotherapy agent used in the treatment of various cancers, including ovarian, lung, head and neck, testicular, and bladder cancer. It is administered intravenously in 50 mg/5 mL, 150 mg/15 mL, and 450 mg/45 mL formulations. Carboplatin interferes with the DNA of cancer cells, preventing their division and growth. Manufactured under stringent GMP regulations, it offers key opportunities for B2B oncology pharmaceutical companies targeting hospitals, oncology clinics, and cancer treatment centers in the US and EU markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing